5 Biotech Stocks to Buy Today According to Ken Fisher

2. Novartis AG (NYSE:NVS)

Fisher Asset Management’s Stake Value: $908 million

Percentage of Fisher Asset Management’s 13F Portfolio: 0.5%

Number of Hedge Fund Holders: 25

Novartis AG (NYSE:NVS) is a healthcare company that sells pharmaceutical products and materials used in medicine production. Its contract manufacturing services allow biotechnology firms to manufacture their products according to the precise demands of the industry.

Novartis AG (NYSE:NVS) reported $13.3 billion in revenue and $1.40 in non-GAAP EPS by the end of its fiscal Q4. This saw the company miss analyst estimates for both metrics. Stifel set a CHF87 price target for the company in February 2022, sharing that the company’s stock has needlessly underperformed the broader market.

Fisher Asset Management owned 10 million Novartis AG (NYSE:NVS) shares by the end of the fourth quarter of 2021, letting it hold a $908 million stake and making it the company’s largest investor according to Insider Monkey’s research. Apart from Mr. Fisher, 25 out of the 924 hedge funds polled by us had invested in the firm.